Paper Details

  1. Home
  2. Paper Details

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.

Author: AllmanD S, BakerT W, ChernoffS B, FergusonB B, FernandoI J, GroteT H, KrisM G, NavariR M, NelsonA M, PendergrassK B, PizzoB A, ThomasV

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study evaluated the effectiveness of a combination of oral dolasetron and dexamethasone in preventing acute emesis in cancer patients receiving cisplatin.
Paper Details　
Original Abstract of the Article :
Dolasetron is a 5-HT3 antagonist antiemetic with active oral and intravenous formulations. The effects of this class are enhanced when combined with dexamethasone. This study tested the ability of the combination of oral dolasetron 200 mg and oral dexamethasone 20 mg to prevent acute emesis in cance...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.1997.15.5.2135

データ提供：米国国立医学図書館（NLM）

Combating Chemotherapy-Induced Nausea and Vomiting: Dolasetron and Dexamethasone

Chemotherapy, a vital component of cancer treatment, often comes with debilitating side effects, particularly nausea and vomiting. This research investigates the effectiveness of a combination of oral dolasetron and dexamethasone in preventing acute emesis in cancer patients receiving high-dose cisplatin, a chemotherapy drug known for its emetic properties. The study explores the potential of this drug combination to improve the quality of life for patients undergoing chemotherapy.

Dolasetron and Dexamethasone: A Powerful Antiemetic Combination

The study demonstrates the efficacy of the combination of oral dolasetron and dexamethasone in preventing acute emesis in patients receiving high-dose cisplatin. The findings suggest that this drug combination can effectively reduce nausea and vomiting, improving patient comfort and enhancing the overall chemotherapy experience. The study underscores the importance of managing chemotherapy-induced side effects to optimize patient well-being and ensure successful cancer treatment.

Managing Chemotherapy Side Effects: Enhancing Patient Comfort

This research highlights the importance of effectively managing chemotherapy-induced side effects, such as nausea and vomiting, to improve patient comfort and enhance the overall chemotherapy experience. The study underscores the need for a multidisciplinary approach to cancer care, ensuring that patients receive comprehensive support and symptom management strategies throughout their treatment journey. It's like preparing a camel caravan for a long and arduous journey, equipping it with essential supplies and resources to navigate the challenges of the desert terrain.

Dr.Camel's Conclusion

This study offers a beacon of hope for patients undergoing chemotherapy, demonstrating the effectiveness of a drug combination in preventing acute emesis and improving patient comfort. It reminds us that the fight against cancer is not only about eradicating the disease but also about supporting the well-being of patients throughout their treatment journey. Just as a camel caravan relies on a strong and supportive network to navigate the challenges of the desert, so too can cancer patients benefit from a compassionate and multidisciplinary care team that ensures their comfort and well-being.

Date :
  1. Date Completed 1997-06-16
  2. Date Revised 2017-02-10
Further Info :

Pubmed ID

9164228

DOI: Digital Object Identifier

10.1200/JCO.1997.15.5.2135

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.